Publication date: Mar 13, 2019
This post was originally published on this site The National Multiple Sclerosis Society is funding a new Phase 2 clinical trial to test the effectiveness of stem cell therapy on individuals with progressive forms of multiple sclerosis (MS), using mesenchymal stem cells from their own bone marrow. Once mesenchymal stem cells are infused, they are believed to secrete growth factors that stimulate the repair of damaged tissues, and possibly act as inhibitors of immune responses associated with MS. The placebo-controlled, Phase 2 trial will test the effectiveness of autologous cell therapy with mesenchymal stem cells-neural progenitors in 50 participants with progressive forms of MS. Participants will receive six injections of culture-expanded autologous stem cells at two month intervals in one year. The post Phase 2 Trial Will Assess Autologous Mesenchymal Stem Cell Therapy to Treat Progressive Forms of MS appeared first on Multiple Sclerosis News Today. The post Phase 2 Trial Will Assess Autologous Mesenchymal Stem Cell Therapy to Treat Progressive Forms of MS appeared first on BioNewsFeeds.
|drug||DRUGBANK||Mesenchymal Stem Cells|
- Cleveland Clinic Chosen for Phase 2 Trial Testing NurOwn Stem Cell Therapy in Progressive MS Patients
- Multiple Sclerosis Relapses Don’t Necessarily Occur After Pregnancy
- Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.
- Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS